Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/15 | $72,500,000 | Series C |
BioMed Ventures Franklin Advisers Janus Capital New Leaf Venture Partners Sofinnova Ventures Venrock | undisclosed |
